Objective:

To explore the use of pulsed electric field ablation for treating various tumors and enhancing the immune response.

Key Findings:

• Pulsed electric field ablation can treat various cancers, including early-stage and advanced tumors, and is FDA approved for specific lesions.
• The procedure is less invasive, leading to faster recovery and same-day discharge for patients.
• It may generate a systemic immune response, aiding in the recognition of tumor antigens and potentially improving overall treatment outcomes.

Interpretation:

This innovative approach may shift treatment paradigms for both early-stage and advanced cancers, offering a safer and more effective alternative to traditional thermal ablation methods.

Limitations:

• Still accumulating data on long-term efficacy and safety.
• Currently limited to specific patient profiles, such as those with tumors near critical structures or those with metastatic disease.

Conclusion:

Pulsed electric field ablation represents a promising advancement in cancer treatment, with potential benefits for patient recovery and immune system activation.